Telix Pharmaceuticals income statement data for the quarter ended Jun 2026. This income statement covers 4 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2023 | Dec2024 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Additional items | ||||
| Shares Outstanding | 319.18M | 331.23M | 337.88M | 337.88M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 323.71M | 345.19M | 337.88M | 337.88M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 323.73M | 334.72M | 338.78M |